Grant: Project Grant
Centre hospitalier de l'Université de Montréal (CHUM)
$1,013,625.00
Deciphering the role of protease-activated receptor 2 in immuno-oncology
EF 2023-24
Résumé
We recently identified Protease-activated receptor 2 (PAR2) as a biomarker of resistance to cancer immunotherapy in patients. PAR2 and its activating proteases are upregulated in different cancers and are expressed by various cells. PAR2 is known to have immune regulatory functions, but its role on cancer immunity remains largely unknown. We hypothesize that PAR2 may represents a promising new therapeutic target. The objective of this project is to investigate the mechanism by which PAR2 expressed on different cells regulate tumor immunity and test the therapeutic activity of a pharmacological inhibitor of PAR2 in combination with standard immunotherapies targeting PD-1 or CTLA-4.
Programme
Project Grant
Emplacement
Quebec, Canada
Type de bénéficiaire
Not-for-profit organization or charity
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
488385
Name
Stagg John
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Biology & Therapeutics
Projecttitle
Deciphering the role of protease-activated receptor 2 in immuno-oncology
Programtype2
Operating Grants
Orgnameinp2
Centre hospitalier de l'Université de Montréal (CHUM)
Cihramount2
$1,013,625
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Immunotherapy
Abstract
We recently identified Protease-activated receptor 2 (PAR2) as a biomarker of resistance to cancer immunotherapy in patients. PAR2 and its activating proteases are upregulated in different cancers and are expressed by various cells. PAR2 is known to have immune regulatory functions, but its role on cancer immunity remains largely unknown. We hypothesize that PAR2 may represents a promising new therapeutic target. The objective of this project is to investigate the mechanism by which PAR2 expressed on different cells regulate tumor immunity and test the therapeutic activity of a pharmacological inhibitor of PAR2 in combination with standard immunotherapies targeting PD-1 or CTLA-4.
Competitiondate
202309
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Stagg, John
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $1,013,625~ $0~
